Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 adjusted net income of $3.89 per diluted share, up from $3.60 a year earlier.
Analysts polled by Capital IQ expected $3.88.
Revenue for the quarter ended June 30 was $2.49 billion, up from $2.2 billion a year earlier.
Analysts surveyed by Capital IQ forecast $2.42 billion.
The biotech firm said it now expects fiscal 2023 revenue of $9.7 billion to $9.8 billion, up from $9.55 billion to $9.7 billion previously. Analysts polled by Capital IQ are looking for $9.75 billion.